5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical Studies

References

• Lokich J, Bothe A, Fine N, et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568
   PubMed Web of Science ®Google Scholar
• Carlson R W, Sikic B I. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99: 823–833
   PubMed Web of Science ®Google Scholar
• Vogelsang N. Continuous infusion chemotherapy. A critical review. J Clin Oncol 1984; 2: 1289–1304
   PubMed Web of Science ®Google Scholar
• Belt R J, Davidner M L, Myron M C, et al. Continuous low-dose 5-fluorouracil (5-FU) for adenocarcinoma: Confirmation of activity. Proc ASCO 1985; 4: 90 (C-349)
   Google Scholar
• Benedetto P, Bogos M, Morillo G, et al. Chronic continuous infusion of 5-fluorouracil (CCI-FU) in previously untreated patients with measurable metastatic colorectal cancer. Proc ASCO 1986; 5: 92, (358)
   Google Scholar
• Caballero G A, Ausman R K, Quebbeman E J. Long term, ambulatory, continuous intravenous infusion of 5-fluorouracil for treatment of advanced adenocarcinomas. Cancer Treat Rep 1985; 69: 13–15
   PubMedGoogle Scholar
• Faintuch J S, Shepard K V, Gaynor E, et al. Continuous infusion 5FU—a dose escalating schedule. Proc ASCO 1986; 5: 93, (363)
   Google Scholar
• Hansen R, Quebbeman E, Ausman R, et al. Continuous systemic 5-fluorouracil (5-FU) infusion in advanced colorectal cancer. Results in 91 patients. J Surg Oncol 1989; 40: 177–181
   PubMed Web of Science ®Google Scholar
• Kuo S, Finck S, Cho J, et al. Continuous ambulatory infusional 5-fluorouracil (5FU) chemotherapy in advanced colorectal cancer: A single institutional retrospective study. Proc ASCO 1989; 8: 126
   Google Scholar
• Leichman L, Leichman C G, Kinzie J, et al. Long-term low dose 5-fluorouracil (5FU) in advanced measurable colon cancer: No correlation between toxicity and efficacy. Proc ASCO 1985; 4: 86, (C-333)
   Google Scholar
• Lokich J, Fine N, Perri J, et al. Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol 1983; 6: 103–107
   PubMed Web of Science ®Google Scholar
• Quebbeman E, Ausman R, Hansen R, et al. Long term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. J Surg Oncol 1985; 30: 60–65
   PubMed Web of Science ®Google Scholar
• Reiter B, Schreibman S, Adler S, et al. Treatment of colorectal cancer with 5FU by infusion in a community oncology practice. Proc ASCO 1987; 6: 74, (288)
   Google Scholar
• Wade J L, Herbst S, Greenburg A. Prolonged venous infusion (PVI) or 5-fluorouracil (5-FU) for metastatic colon cancer. A follow-up report. Proc ASCO 1988; 7: 94
   Google Scholar
• Lokich J, Ahlgren J, Gullo J, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Lokich J J. Cancer Chemotherapy by Infusion. Precept Press, Chicago 1990; 328–329
   Google Scholar
• Weinerman B, Shah A, Fields A, et al. A randomized trial of continuous systemic infusion vs bolus therapy with 5 fluorouracil in metastatic measurable colorectal cancer. Proc ASCO 1990; 9: 103
   Google Scholar
• Hansen R, Quebbeman E, Beatty P, et al. Continuous 5-fluorouracil (5-FU) infusion in refractory carcinoma of the breast. Breast Cancer Treat Res 1987; 10: 145–149
   PubMed Web of Science ®Google Scholar
• Hatfield A K, Johnson P A, Egner J R, et al. Long term continuous 5-fluorouracil (5-FU) infusion in the treatment of far advanced metastatic breast carcinoma. Proc ASCO 1989; 8: 35
   Google Scholar
• Hatfield A K, Neuberg D S, Berris R F, et al. Clinical trial of continuous intravenous infusion (CTT) of 5-FU or doxorubicin (DOX) in metastatic breast carcinoma: An Eastern Cooperative Oncology Group Study (ECOG). Proc ASCO 1989; 8: 35
   Google Scholar
• Huan S, Pazdur R, Singhakowinta A, et al. Low dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer 1989; 63: 419–422
   PubMed Web of Science ®Google Scholar
• Jabboury K, Holmes F, Hortobagyi G, et al. fluorouracil rechallenge by protracted continuous infusion in refractory breast cancer. Cancer 1989; 64: 793–797
   PubMed Web of Science ®Google Scholar
• Strauss G, Schwartz J, Nickerson J, et al. Continuous infusion (CI) 5-fluorouracil (5-FU) with or without cisplatin as third-line therapy for metastatic breast cancer. Proc ASCO 1988; 7: 39
   Google Scholar
• Moynihan T, Hansen R, Anderson T, et al. Continuous 5-Fluorouracil (5-FU) infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11: 461–464
   PubMed Web of Science ®Google Scholar
• Hansen R, Quebbeman E, Ritch P, et al. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas. Am J Med Sci 1988; 295: 91–93
   PubMed Web of Science ®Google Scholar
• Hansen R, Moynihan T, Beatty P, et al. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 1991; 37: 358–361
   PubMed Web of Science ®Google Scholar
• Lokich I I, Rich T, Chaffey J. Protracted infusion 5-fluorouracil in gastrointestinal malignancy. Neo-Adj Chemother 1986; 137: 683–689
   Google Scholar
• Lokich J, Ahlgren J, Gullo J, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Lokich J, Cantrell J, Ahlgen J, et al. A phase III trial of protracted infusion 5FU (PIF) vs PIF plus weekly bohis cisplatin (CDDP) in advanced measurable colon cancer (MAOP protocol 5286). Proc ASCO 1989; 8: 104
   Google Scholar
• Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin Oncol, 5: 1559–1565
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglass H O, Jr, Hen-Era L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–1426
   PubMed Web of Science ®Google Scholar
• Nobile M T, Vidtti M G, Sobrero A, et al. 5-Fluorouracil alone or combined with high dose folinic acid in advanced colorectal cancer patients: A randomized trial. Proc ASCO 1988; 7: 97
   Google Scholar
• Valone F H, Friedman M A, Wittlinger P S, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil, leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427–1436
   PubMed Web of Science ®Google Scholar
• Costanzo F D, Bartolucci R, Sofra M, et al. 5-Fluorouracil alone versus high dose folinic acid and 5-FU in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research. Proc ASCO 1989; 8: 106
   Google Scholar
• Labianca R, Pancera G, Beretta G, et al. A randomized study of intravenous fluorouracil plus or minus folinic acid in advanced metastatic colorectal carcinoma. Proc ASCO 1989; 8: 118
   Google Scholar
• Doroshow J H, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491–501
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475
   PubMed Web of Science ®Google Scholar
• Waaler S, Schwartz F X. Goldman Metal: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–1775
   PubMed Web of Science ®Google Scholar
• Kemeny N, Kelsen D, Derby S, et al. Combination of 5-fluorourcil (5FU) and recombinant alpha-interferon (IFN) in advanced colorectal carcinoma: activity but significant toxicity. Proc ASCO 1990; 9: 109
   Google Scholar
• Pazdur R, Abbruzzese J, Faintuch J, et al. Phase II study of recombinant interferon alpha (rJFN) and 5-fluorouracil (SFU) in patients with advanced colorectal carcinoma. Proc ASCO 1990; 9: 117
   Google Scholar
• Huberman M, Bering H, Tessitore J, et al. 5-Fluorouracil (5FU) plus recombinant alpha interferon in advanced colorectal cancer. Proc ASCO 1990; 9: 116
   Google Scholar